Orexin-A

What is Orexin-A?

Orexin-A (also called Hypocretin-1) is a 33-amino acid neuropeptide produced by neurons in the lateral hypothalamus. It is a master regulator of the sleep-wake cycle, arousal, and energy homeostasis. Loss of orexin-producing neurons causes narcolepsy type 1. Research into orexin replacement therapy and orexin receptor agonists is active.

What Orexin-A Is Investigated For

Orexin-A is the endogenous wakefulness-promoting neuropeptide whose loss causes narcolepsy type 1, and research interest centers on replacement therapy for narcolepsy, promotion of alertness and wakefulness, and to a lesser extent metabolic and appetite regulation. The strongest mechanistic case is in narcolepsy type 1 — where orexin deficiency is the defining pathology — and small intranasal studies have reported acute improvements in sleep, attention, and olfaction in narcoleptic patients. However, the translational future of orexin pharmacology has shifted decisively to oral small-molecule OX2R agonists (TAK-861/oveporexton, ORX750), which are in Phase II/III trials and likely to dominate narcolepsy treatment going forward; peptide-based orexin-A as a chronic replacement therapy has not advanced through controlled long-term human trials. Use in healthy adults for cognition or alertness has no rigorous clinical basis, and exogenous augmentation raises plausible cardiovascular and sympathetic concerns given orexin's pressor effects. Active drug-development target, not an established therapy.

History & Discovery

Orexin-A — also called hypocretin-1 — was discovered in 1998 by two independent research groups within weeks of each other. Luis de Lecea and J. Gregor Sutcliffe at the Scripps Research Institute identified the peptides via subtractive hybridization for hypothalamic-specific transcripts and named them 'hypocretins' for their hypothalamic origin and structural relationship to the secretin peptide family. Almost simultaneously, Takeshi Sakurai and Masashi Yanagisawa at UT Southwestern identified the same peptides as ligands for orphan G-protein-coupled receptors and named them 'orexins,' from the Greek for appetite, based on their initial observation that intracerebroventricular injection increased food intake in rats. Both names persist in the literature; 'orexin' tends to dominate clinical neurology and 'hypocretin' tends to dominate basic neuroscience. The field's defining moment came two years later. In 2000, Emmanuel Mignot's group at Stanford and Christian Bassetti's collaborators showed that human narcolepsy with cataplexy is associated with severe loss of orexin-producing neurons in the lateral hypothalamus, and that cerebrospinal fluid orexin-A is essentially undetectable in those patients. That single finding redefined narcolepsy type 1 as an orexin-deficiency disorder and reframed the orexin system as a therapeutically tractable target for both wake-promoting and sleep-promoting drug development. The first wave of clinical translation went in the antagonist direction: dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant — became approved insomnia drugs in the 2010s and early 2020s. The second wave, now the most active area of clinical work, is in orexin agonists: oral OX2R agonists (Takeda's TAK-861/oveporexton, Centessa's ORX750, and others) are in Phase II/III for narcolepsy and idiopathic hypersomnia in 2024–2025. Intranasal orexin-A as a peptide replacement therapy was tested in narcolepsy in small studies in the 2000s and 2010s but has been largely overtaken by the small-molecule oral agonist program.

How It Works

Orexin-A is the brain's 'wake-up signal.' It activates arousal centers throughout the brain, keeping you alert and awake. When orexin neurons are destroyed (as in narcolepsy), people experience uncontrollable sleepiness.

Orexin-A binds to both OX1R and OX2R (orexin receptors 1 and 2), which are GPCRs expressed widely in the brain including the locus coeruleus, tuberomammillary nucleus, raphe nuclei, and ventral tegmental area. It activates noradrenergic, histaminergic, serotonergic, and dopaminergic arousal systems. OX2R is particularly important for sleep-wake regulation. Orexin-A also regulates the HPA axis, sympathetic tone, and energy metabolism. It has a disulfide bond that stabilizes its structure and distinguishes it from Orexin-B.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Orexin-A:

• 01Chronic intranasal orexin-A safety and efficacy in narcolepsy — small acute studies exist, but no controlled long-term replacement-therapy trial has been completed.
• 02Comparative efficacy and durability versus oral OX2R agonists — as the small-molecule program reaches Phase III, head-to-head data with peptide replacement would clarify whether peptide therapy retains any niche.
• 03Use in narcolepsy type 2 and idiopathic hypersomnia — most data is in narcolepsy type 1 (orexin-deficient by definition), and whether exogenous orexin helps conditions where the orexin system is intact is unclear.
• 04Cardiovascular safety with chronic use — orexin's sympathoexcitatory effects raise long-term cardiovascular concerns that have not been studied across years of replacement.
• 05Use in healthy adults for cognition or alertness — there is no rigorous clinical evidence that exogenous orexin-A meaningfully enhances wakefulness or cognition in non-deficient individuals, and the safety basis for off-label use is absent.
• 06Reproductive, pediatric, and pregnancy data — no studies in any of these populations.

Forms & Administration

Intranasal spray (research). Oral orexin receptor agonists are in clinical development. Not widely available outside research settings.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Orexin-A is not approved for any therapeutic indication anywhere. It is a research peptide and a target of active drug development, not a treatment. Self-administered intranasal orexin-A from research-chemical sources carries unknown content, unknown sterility, and no dose-response basis in humans.

Timeline of Effects

Common Questions

Who Orexin-A Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for orexin-A in humans are limited because human use is limited. The most concrete interaction is conceptual rather than empirical: dual orexin receptor antagonists (DORAs — suvorexant, lemborexant, daridorexant) are designed to block exactly the receptors orexin-A activates. Co-use would be pharmacologically self-defeating and is not described in any clinical context. Patients on a DORA for insomnia should not be exposed to exogenous orexin-A. With stimulants and other wake-promoting agents (modafinil, armodafinil, amphetamines, methylphenidate, solriamfetol, pitolisant), the additive arousal and cardiovascular load is plausible but not formally characterized. Cardiovascular stimulation from orexin-A on top of these drugs could produce additive blood pressure and heart rate effects. With antihypertensives and rate-control medications, orexin-A's sympathetic activation could partially offset their effect. With opioids and benzodiazepines (which suppress orexin signaling indirectly via central depression), the interaction direction is unpredictable in humans. As with any peptide of unverified clinical pharmacology, patients on regular medications should disclose any orexin-A use to their prescriber. Absence of documented interaction reflects absence of human use rather than absence of risk.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions